Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago. The drugmaker also said Wednesday that it will ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. The first new Alzheimer’s treatment in more ...

The U.S. Food and Drug Administration's approval of Biogen's Alzheimer's drug Aduhelm in June was heralded as a historic triumph in the fight against a disease that kills thousands of Americans every ...

Excellus BlueCross BlueShield joins the ranks of six Blue Cross Blue Shield affiliates who are refusing to cover Aduhelm, Biogen’s Alzehimer’s drug, without definite proof of its effectiveness.

WASHINGTON (AP) — The Food and Drug Administration (FDA) has approved new prescribing instructions that are likely to limit the use of a controversial new Alzheimer's drug. The update comes one month ...

CMS intends for Medicare to cover Aduhelm, Biogen’s Alzheimer’s disease treatment, for patients taking part in clinical trials, the agency announced Jan. 11. The national coverage determination ...

Department of Health and Human Services Secretary Xavier Becerra announced Monday that he has ordered Medicare to "reassess" the agency's 2022 premium rate hike for Medicare Part B, citing Biogen's ...

News moves fast, and there's not always time to untangle the complex forces driving the day's biggest stories. WSJ Explains breaks down big market moves, business and economic trends, and scientific ...

A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's accelerated approval process, and is using treatments from Sarepta Therapeutics ...

The release by the U.S. CMS of the final national coverage determination (NCD) for Biogen Inc.’s Alzheimer disease (AD) drug, Aduhelm (aducanumab), lit speculation on the meaning for others in the ...

A month after approving a controversial new Alzheimer’s drug, U.S. health regulators on Thursday signed off on new prescribing instructions that are likely to limit its use. The Food and Drug ...